Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial
The trial is evaluating nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).
Related stories
Air Travel Disruptions Expected to Persist Into Sunday, Officials Say
Officials say thousands of flights are affected as air travel issues are expected to continue well into Sunday.
M impact | EQUITY | Nov 14, 2026, 11:56 PM UTC
SpaceX Starship Returns to Landing Pad After 22-Hour Orbital Voyage
SpaceX’s Starship returned from a 22-hour voyage in orbit and was caught by mechanical arms at the Texas launch tower, a first for the spacecraft.
M impact | EQUITY | Nov 14, 2026, 10:39 PM UTC
SpaceX Starship Returns to Landing Pad From Orbit
SpaceX’s Starship returned to its landing pad from orbit, completing a test of reusable rockets.
M impact | EQUITY | Nov 14, 2026, 10:39 PM UTC
Air Travel Disruptions to Persist Into Sunday, Officials Say
Officials say thousands of flights have been affected, with air travel issues expected to persist well into Sunday.
M impact | EQUITY | Nov 14, 2026, 09:39 PM UTC
SpaceX Starship Returns to Texas Launch Tower After Orbital Flight
SpaceX’s Starship spacecraft returned Saturday to the Texas launch tower from which it launched a day earlier, completing the rocket system’s first key recovery, according to the r
M impact | EQUITY | Nov 14, 2026, 09:22 PM UTC
More Than 10,000 Flights Delayed or Canceled Saturday
Airlines are working to restore normal schedules.
M impact | EQUITY | Nov 14, 2026, 07:34 PM UTC